Tristel Regulatory News (TSTL)

Tristel plc

("Tristel" or "the Company")

Trading Update

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, provides a trading update for the year ending 30 June 2014, showing results ahead of previously upgraded expectations.

Tristel addresses three distinct markets: Human Healthcare, Animal Healthcare and Contamination Control, with three distinctively branded product ranges: Tristel, Anistel and Crystel.

Tristel announced in its Interim Statement on 3 March 2014 that it had experienced a strong start to the second half across all areas of the business. The Company is now confident that the momentum evident throughout the first half will continue through to the end of the financial year and beyond, resulting in pre-tax profit for the year to 30 June 2014 of no less than £1.5m (2013: £0.4m adjusted pre-tax profit*). This level of profit is ahead of current market expectations.

The balance sheet continues to strengthen with cash balances exceeding £2.2m (£1.5m at 31 December 2013). 

Paul Swinney, Chief Executive, comments "The momentum that we have built since the beginning of 2013 is gathering pace both in the UK and overseas markets and across all three product portfolios. Over the past three years the business has undergone a transformation to focus upon innovative consumable products which are essential within the healthcare setting. One recent success has been our inclusion in the NHS Scotland framework agreement for surface disinfectant products." 

*Adjusted for non-recurring items of £2.2m

For further information please contact: